Author/Editor		Popovič, Peter; Šurlan, Miloš; Kuhelj, Dimitrij
Title		Kemoembolizacija hepatoceličnega karcinoma
Translated title		Chemoembolization of hepatocellular carcinoma
Type		članek
Source		In: Repše S, Stanisavljevič D, editors. Zbornik simpozija Kirurgija jeter in vranice; 2004; Ljubljana. Ljubljana: Kirurška šola, Klinični oddelek za obdominalno kirurgijo,
Publication year		2004
Volume		str. 79-91
Language		slo
Abstract		Background. Hepatocellular carcinoma (HCC) is a common, difficult to treat cancer. Current treatment are surgical resection and liver transplantation. In patients who are unsuitable candidates for surgery, local ablation therapies appear to be valid mainly for treatment of single neoplastic lesions smaller than 3-4 cm in diameter. Systemic chemotherapy is mostly inactive. The dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatocellular carcinoma. Chemoembolization is a well-established technique combining intraarterial chemotherapy (mytomicin) with Lipiodol and delivery of embolic agents (Ivalon, Biospherej. In this article authors describe the role of chemoembolization (TACE) in the management of HCC. A clear presentation of TACE indications and contraindications is given. A detailed description of the procedure, complications, therapeutic results and a postprocedure follow-up are given.
Descriptors		LIVER NEOPLASMS CHEMOEMBOLIZATION, THERAPEUTIC EMBOLIZATION, THERAPEUTIC PALLIATIVE CARE MITOMYCINS